Progressive Supranuclear Palsy- Pipeline Insight, 2025

This “Progressive Supranuclear Palsy- Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Progressive Supranuclear Palsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Progressive Supranuclear Palsy: Understanding

Progressive Supranuclear Palsy: Overview

Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disorder caused by the accumulation of tau protein in the brain. It primarily affects movement, balance, speech, vision, and cognition. Early symptoms often include frequent falls, difficulty with eye movements (especially looking down), and stiffness in the neck. As the disease progresses, individuals may experience slurred speech, swallowing difficulties, and behavioral changes. PSP is often misdiagnosed as Parkinson's disease due to overlapping symptoms but lacks the significant tremors. Currently, there is no cure, and treatment focuses on symptom management and supportive care.

Progressive Supranuclear Palsy (PSP) is characterized by early postural instability, frequent falls, and difficulty with voluntary eye movements, especially looking down. Other symptoms include stiffness, slurred speech, swallowing difficulties, and a slow, stiff gait. Cognitive changes, such as apathy and impaired judgment, may also occur. Unlike Parkinson's, PSP lacks significant tremors and is resistant to dopaminergic therapy. PSP affects approximately 3-6 people per 100,000, typically after the age of 60. It is caused by abnormal deposits of tau protein in the brain, leading to neurodegeneration. PSP is characterized by difficulty with vertical eye movements, frequent falls, postural instability, and stiffness. It is often mistaken for Parkinson's disease or other neurological disorders due to overlapping symptoms. Current treatments focus on symptom management, including medications, therapy, and supportive care.

Certain factors may increase your risk of developing Progressive Supranuclear Palsy. These include genetic predisposition mutations or variations in the MAPT gene, which codes for the tau protein, may increase the risk. PSP typically occurs in individuals over the age of 60.Some studies suggest that exposure to certain toxins or chemicals may play a role, though evidence is limited. PSP is slightly more common in men than in women. Abnormal accumulation of tau protein in the brain is a hallmark, though the triggers for this dysfunction are unclear. The diagnosis of Progressive Supranuclear Palsy (PSP) is primarily clinical, based on a detailed medical history, symptom evaluation, and neurological examination. Key diagnostic features include difficulty with vertical eye movements, frequent falls, postural instability, and progressive stiffness. Brain imaging, such as MRI, may show midbrain atrophy (the 'hummingbird sign') and exclude other conditions. Genetic testing for MAPT mutations may be considered in rare cases. Since no definitive test exists, PSP is often misdiagnosed, particularly in its early stages.

There is no cure for Progressive Supranuclear Palsy (PSP), and treatment focuses on managing symptoms and improving quality of life. Medications like levodopa may provide limited relief for stiffness and slowness, but their effects are often temporary. Physical and occupational therapy can help improve mobility, balance, and daily functioning. Speech therapy is beneficial for addressing speech and swallowing difficulties. Assistive devices, such as walkers and glasses with prisms, may aid in mobility and vision. Supportive care, including counseling and nutritional management, is essential as the disease progresses.

'Progressive Supranuclear Palsy- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Progressive Supranuclear Palsy pipeline landscape is provided which includes the disease overview and Progressive Supranuclear Palsy treatment guidelines. The assessment part of the report embraces, in depth Progressive Supranuclear Palsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Progressive Supranuclear Palsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Progressive Supranuclear Palsy R&D. The therapies under development are focused on novel approaches to treat/improve Progressive Supranuclear Palsy.

Progressive Supranuclear Palsy Emerging Drugs Chapters

This segment of the Progressive Supranuclear Palsy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Progressive Supranuclear Palsy Emerging Drugs

AMX0035: Amylyx Pharmaceuticals

AMX0035 is an oral, fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO; also known as ursodoxicoltaurine outside of the U.S.). AMX0035 was designed to slow or mitigate neurodegeneration by targeting endoplasmic reticulum (ER) stress and mitochondrial dysfunction, two connected central pathways that lead to cell death and neurodegeneration. We believe that our proprietary combination of PB and TURSO and their complementary mechanisms of action will allow us to synergistically target abnormal cell death to better prevent neurodegeneration than treatment targeted at either mechanism of action alone. AMX0035 is being studied as a potential treatment for Wolfram syndrome and progressive supranuclear palsy, two neurodegenerative diseases. The drug is currently being investigated in the Phase II/III stage of development for the treatment of Progressive Supranuclear Palsy.

TPN-101: Transposon Therapeutics, Inc.

TPN-101 specifically inhibits the LINE-1 reverse transcriptase that promotes LINE-1 replication. LINE-1 elements are a class of retrotransposable elements that in humans are uniquely capable of replicating and moving to new locations within the genome. When this process becomes dysregulated, LINE-1 reverse transcriptase drives overproduction of LINE-1 DNA, triggering innate immune responses that contribute to neurodegenerative, autoimmune and aging-related disease pathology. Currently, the drug is in the Phase II stage of its development for the treatment of progressive supranuclear palsy.

Progressive Supranuclear Palsy: Therapeutic Assessment

This segment of the report provides insights about the different Progressive Supranuclear Palsy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Progressive Supranuclear Palsy

There are approx. 10+ key companies which are developing the therapies for Progressive Supranuclear Palsy. The companies which have their Progressive Supranuclear Palsy drug candidates in the most advanced stage, i.e. Phase II/III include, Amylyx Pharmaceuticals.

Phases

The report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Progressive Supranuclear Palsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Progressive Supranuclear Palsy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Progressive Supranuclear Palsy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Progressive Supranuclear Palsy drugs.

Progressive Supranuclear Palsy Report Insights

• Progressive Supranuclear Palsy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Progressive Supranuclear Palsy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Progressive Supranuclear Palsy drugs?
• How many Progressive Supranuclear Palsy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Progressive Supranuclear Palsy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Progressive Supranuclear Palsy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Progressive Supranuclear Palsy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Amylyx Pharmaceuticals
• Transposon Therapeutics, Inc
• Ferrer International
• Novartis Pharmaceuticals
• TauC3 Biologics

Key Products

• AMX0035
• TPN-101
• FNP-223
• NIO 752
• TBL-100

This product will be delivered within 2 business days.